Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BeOne Medicines Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd., a Switzerland-based biopharmaceutical group listed in Hong Kong, develops innovative drug candidates with a focus on hematology and other specialty therapies. The company is expanding globally and aligns its reporting with both U.S. GAAP and international listing standards, reflecting its dual-market regulatory and investor base.
The company released unaudited consolidated results for the fourth quarter and audited results for the full year ended 31 December 2025, along with 2026 financial guidance and business updates prepared under U.S. GAAP. Management cautioned investors that the guidance is based on preliminary assessments, may differ from IFRS-based figures to be disclosed by 31 March 2026, and should be treated carefully given clinical, regulatory and commercial risks highlighted in its risk disclosures.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.
More about BeOne Medicines Ltd
BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercializing hematology and other innovative medicines. The group operates globally and reports its financials under U.S. GAAP, while also complying with Hong Kong listing requirements and SEC disclosure rules.
Average Trading Volume: 3,313,309
Technical Sentiment Signal: Buy
Current Market Cap: HK$348B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.